phenazolam

{{Short description|Benzodiazepine designer drug}}

{{Drugbox

| IUPAC_name = 8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine

| image = Clobromazolam_structure.png

| image_class = skin-invert-image

| tradename = (none, designer drug)

| legal_CA = Schedule IV

| legal_DE = NpSG

| legal_UK = PSA

| legal_US =

| legal_status = Illegal in Serbia and Italy

| bioavailability =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 87213-50-1

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 2AVB9ZZ4ZS

| PubChem = 1032830

| ChemSpiderID = 887985

| ChEMBL = 1451229

| DTXSID = DTXSID10236191

| C=17 | H=12 | Br=1 | Cl=1 | N=4

| SMILES = CC1=NN=C2N1C3=C(C=C(C=C3)Br)C(=NC2)C4=CC=CC=C4Cl

| StdInChI=1S/C17H12BrClN4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3

| StdInChIKey = BUTCFAZTKZDYCN-UHFFFAOYSA-N

}}

Phenazolam, (Clobromazolam, DM-II-90, BRN 4550445) is a benzodiazepine derivative which acts as a potent sedative and hypnotic drug. It was first invented in the early 1980s,{{cite journal | vauthors = Polívka Z, Holubek J, Metyš J, Šedivŷ Z, Protiva M | title = Potential hypnotics and anxiolytics: 8-Chloro-6-(2-chlorophenyl)-1-[4-(2-methoxyethyl) piperazino]-methyl-4H-s-triazolo[4,3-a]-1,4-benzodiazepine and related compounds. | journal = Collection of Czechoslovak Chemical Communications | date = 1983 | volume = 48 | issue = 12 | pages = 3433–43 | doi = 10.1135/cccc19833433 }} but was never developed for medical use. It has been sold over the internet as a designer drug, first being identified in seized samples by a laboratory in Sweden in March 2016.{{cite web | url = https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/881969/ACMD_report_-_a_review_of_the_evidence_of_use_and_harms_of_novel_benzodiazepines.pdf | title = Novel Benzodiazepines. A review of the evidence of use and harms of Novel Benzodiazepines. | publisher = Advisory Council on the Misuse of Drugs | date = April 2020 }}{{cite journal | vauthors = Wagmann L, Manier SK, Felske C, Gampfer TM, Richter MJ, Eckstein N, Meyer MR | title = Flubromazolam-Derived Designer Benzodiazepines: Toxicokinetics and Analytical Toxicology of Clobromazolam and Bromazolam | journal = Journal of Analytical Toxicology | volume = 45| issue = 9| pages = 1014–1027| date = October 2020 | pmid = 33048135 | doi = 10.1093/jat/bkaa161 }}